Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Seimetz, N. Parajuli, A. Pichl, R. T. Schermuly, F. Grimminger, W. Seeger, H. A. Ghofrani, N. Weissmann (Giessen, Germany). Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice. Eur Respir J 2014; 44: Suppl. 58, 3420

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary vessels remodeling in COPD Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 The effect of pulmonary hypertension on aerobic exercise capacity in lung transplant candidates with advanced COPD Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Pulmonary hypertension and COPD: Clinical assessment and biomarkers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 CT measured pulmonary artery to aorta ratio as a predictor of pulmonary hypertension in COPD Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014